MiR-205 expression levels in nonsmall cell lung cancerdo not always distinguish adenocarcinomas from squamous cell carcinomas

American Journal of Surgical Pathology

Volumn 35, Issue 2, 2011, Pages 268-275

  Vescovo, Valerio Del ^a   Cantaloni, Chiara ^b   Cucino, Alberto ^b   Girlando, Salvatore ^c   Silvestri, Massimo ^b   Bragantini, Emma ^b   Fasanella, Silvia ^b   Cuorvo, Lucia Veronica ^b   Palma, Paolo Dalla ^b   Rossi, Giulio ^d   Papotti, Mauro ^e,f   Pelosi, Giuseppe ^g   Graziano, Paolo ^h   Cavazza, Alberto ⁱ   Denti, Michela Alessandra ^a   Barbareschi, Mattia ^b,c  

^a UNIVERSITY OF TRENTO   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c Laboratory of Molecular Pathology   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e SAN LUIGI GONZAGA HOSPITAL   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h SAN CAMILLO FORLANINI HOSPITAL   (Italy)

ⁱ Unit of Pathologic Anatomy   (Italy)

Author keywords

classification; lung cancer; microRNA; miR 205; target therapy

Indexed keywords

MICRORNA; MIRN205 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; RNA; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 79251579006     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182068171     Document Type: Article

References (24)

1. Barbareschi M, Murer B, Colby TV, et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003;27:141-149.
2. Barbareschi M, Togni R, Aldovini D, et al. Tissue microarrays in oncology. Pathologica. 2003;95:265-266.
3. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol. 2004;28: 1169-1176.
4. Bentwich I. Prediction and validation of microRNAs and their targets. FEBS Lett. 2005;579:5904-5910.
5. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010;16:610-619.
6. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
7. Chilosi M, Murer B. Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med. 2010;134:55-65.
8. Demichelis F, Sboner A, Barbareschi M, et al. TMABoost: an integrated system for comprehensive management of tissue microarray data. IEEE Trans Inf Technol Biomed. 2006;10: 19-27.
9. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455: 1069-1075.
10. Gao W, Shen H, Liu L, et al. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2010. [Epub ahead of print].
11. Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16:430-441.
12. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009;27:2030-2037.
13. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undiffer-entiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5:442-447.
14. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
15. Mallick R, Patnaik SK, Yendamuri S. MicroRNAs and lung cancer: Biology and applications in diagnosis and prognosis. J Carcinog. 2010;3:9.
16. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.
17. Neal JW. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist. 2010;15:3-5.
18. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cyto-keratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol. 2010;5:436-441.
19. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol. 2010;23:814-823.
20. Rossi G, Papotti M, Barbareschi M, et al. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol. 2009;27:e141-e142.
21. Rossi G, Pelosi G, Graziano P, et al. Review article: a reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009;17:206-218.
22. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34:1155-1162.
23. Stoll LM, Johnson MW, Gabrielson E, et al. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010;118:441-449.
24. Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol. 2010;23:1157-1164.